Abstract 17837: Patients With Familial Hypercholesterolemia Who Initiated Statin Treatment In Childhood Are At Lower Risk For Chd Then Their Affected Parents
Background: Statins are currently the preferred pharmacological therapy in children with familial hypercholesterolemia (FH) with the aim to prevent premature atherosclerosis and subsequent coronary heart disease (CHD). In this study, we evaluated the risk on CHD in young adult FH patients after 10-years of statin treatment initiated in childhood and their affected parents for whom statins were available from adulthood onwards.
METHODS: All 214 FH children, who were randomized between 1997 and 1999 (8-18 years) into a placebo-controlled trial evaluating the 2-year efficacy and safety of pravastatin, were eligible. After the study, all children were continued on statins and were followed for 10 years. Questionnaires including medical history of first degree relatives with FH were taken.
RESULTS: Follow-up was successful in 95.8% patients (age 18 to 30 years) and 82.4% were still using statins. At the age of 30 years, the CHD free survival was 100% in the group of young adults who initiated statin therapy in childhood and 93% in the affected parents (p=0.023). The FH fathers had suffered significantly more CHD than the FH mothers (cumulative CHD survival at the age of 30 years: 90% and 97%, respectively; p<0.001).
Conclusions: After ten years of treatment, young adult FH patients had not suffered from cardiovascular complaints. Our findings suggest that statin therapy in FH individuals initiated in childhood are effective in reducing the risk of CHD. However, long-term follow-up is needed to confirm these results.
This study was funded by the Dutch Heart Foundation
- © 2013 by American Heart Association, Inc.